Comparative Pharmacology
Head-to-head clinical analysis: LOTRIMIN versus LOTRIMIN ULTRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTRIMIN versus LOTRIMIN ULTRA.
LOTRIMIN vs LOTRIMIN ULTRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Butenafine hydrochloride is a synthetic antifungal agent that inhibits the enzyme squalene epoxidase, thereby blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes, leading to fungal cell death.
Clotrimazole 1% cream or solution applied topically to affected area twice daily for 2-4 weeks. For vaginal tablets: 100 mg intravaginally once daily for 7 days or 500 mg single dose. For troches: 10 mg troche dissolved slowly in mouth five times daily for 14 days.
Adults: Apply butenafine hydrochloride 1% cream topically once daily for 7 days for tinea pedis; for tinea cruris and tinea corporis, apply once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 20-50 hours. Dose adjustments not required in renal impairment, but caution in hepatic impairment.
Terminal elimination half-life is approximately 24-48 hours (range 20-50 hours), supporting once-daily topical application.
Approximately 70% of absorbed dose is excreted in feces as unchanged drug and metabolites; about 20% is excreted renally as metabolites with less than 1% unchanged. Biliary excretion is a minor route.
Primarily fecal (approx. 80%) as unchanged drug and metabolites; renal excretion accounts for <10% of the dose.
Category C
Category C
Topical Antifungal
Topical Antifungal